1. Scope

This summary covers oral creatine monohydrate (CrM).

Covered domains: musculoskeletal ageing (sarcopenia, muscle mass/strength, bone), cognition, mood, cardiometabolic surrogates, mortality signals, dosing, safety and monitoring.

Not covered: intravenous/phosphocreatine formulations for acute cardiac disease, creatine for inborn creatine-synthesis/transporter disorders, paediatric neurological indications, and ergogenic use in elite athletes (referenced only for safety/dosing). Content is intended as adjunctive care alongside conventional primary/secondary care, not a replacement for it. CrM is sold in the UK as a food supplement; all longevity indications below are off-label/non-guideline unless stated.

2. Background and pathophysiology

– Biological rationale: Creatine is stored predominantly in skeletal muscle (~95% of body stores) as phosphocreatine (PCr), a rapidly mobilised phosphate reservoir that regenerates ATP during high-energy demand. The brain also relies on the creatine/PCr system for bioenergetic buffering.[1][2]

– Ageing relevance: Endogenous synthesis and dietary intake (chiefly red meat) may be insufficient to saturate muscle and brain stores; supraphysiological dosing raises muscle total creatine by ~20–30% and PCr by ~10–15%. Targeted mechanisms with human plausibility include muscle bioenergetics/anabolism (upregulation of myogenic regulatory factors, IGF-1; myostatin suppression), cerebral energy buffering, and modest effects on glucose handling and oxidative/inflammatory markers.[3][1][4][5][6]

– Preclinical only (mechanistic plausibility, not clinical proof): antioxidant/anti-inflammatory signalling, mitochondrial protection, gut-barrier and microbiome effects, and fetal neuroprotection are largely animal/in-vitro or narrative-review derived and should not be presented to patients as established benefits.[4][7][8][9]

3. Evidence base and grading

The evidence base is strongest for muscle mass/strength when CrM is combined with resistance training (RT), moderate/weak for cognition and mood, and weak or null for bone density, cardiometabolic hard outcomes and mortality. GRADE-style certainty below reflects risk of bias, heterogeneity, indirectness to a longevity population, and imprecision.

Outcome	Evidence statement	Certainty (GRADE)	Recommendation	Rationale/limitations
Lean/fat-free mass + strength (with RT) in older adults	Meta-analysis of 357 older adults: CrM+RT increased fat-free mass, chest/leg-press 1RM and chair-stand vs RT alone [10]; corroborated by narrative syntheses [11], [12]	Moderate	Conditional (offer) — combined with RT	Consistent direction; small trials, modest effect sizes; benefit largely absent without RT
Lean mass/strength in postmenopausal women	Meta-analysis (7 RCTs, n=608): +0.37 kg lean mass, +7.5 kg leg-press 1RM, benefit only at ≥5 g/day with RT [13]	Moderate	Conditional (offer) — ≥5 g/day + RT	Small absolute gains; ≤3 g/day without RT ineffective
Memory/cognition, healthy older adults	Meta-analysis (8 RCTs): SMD 0.29 overall, larger in adults 66–76 y (SMD 0.88) [14]; systematic review largely positive but low quality [15]; largest single RCT (n=123) only borderline [16]	Low	Conditional/Only in research	High heterogeneity, small trials, surrogate endpoints, no dementia-outcome data
Depressive symptoms	Meta-analysis (11 RCTs, n=1093): SMD −0.34, below MID, substantial bias favouring creatine [17]; RCT review suggests promise as SSRI/CBT adjunct [18], [19]	Very low	Only in research / specialist adjunct	Average effect not clinically important; publication bias; rare hypomania signal
Glycaemic control	Systematic reviews: benefit mainly with concurrent exercise; small T2DM trials, high RoB [5], [20]	Low	Conditional (adjunct to exercise)	Small samples, not generalisable to insulin-treated/older patients
Bone mineral density	Two 2-yr RCTs (n=237; n=200) showed no BMD benefit; some improvement in femoral geometry only [21], [22], [23]; meta-analysis: BMD unchanged [13]	Moderate (for no effect)	Recommend against (for BMD indication)	Consistent null across best trials
All-cause mortality	Single NHANES cohort: HR 0.85 for ≥1 g/day dietary creatine, attenuated after full adjustment [24]	Very low	Only in research	Observational, dietary-recall, residual confounding; no RCT mortality data
CV/heart failure hard outcomes	Cochrane review: no trials in hypertension; no significant mortality/EF benefit in existing cardiac trials [25]	Very low	Recommend against (as CV therapy)	Small, heterogeneous trials

4. Patient selection and indications

Who may benefit (adjunctive, off-label, with informed consent):

– Middle-aged/older adults undertaking resistance training seeking to augment lean mass, strength and physical function — the best-supported indication.[10][13][12]

– Older adults with, or at risk of, sarcopenia/frailty as an adjunct to a structured RT programme (mechanistically justified; direct frailty-outcome RCTs lacking).[11][26]

– Older adults with subjective memory concern — reasonable to consider given low-certainty cognitive signal and strong safety profile, framed as unproven.[14][15]

– Vegetarians/vegans, who have lower baseline stores and may respond more consistently to loading (physiological rationale).[1]

Exclusion / use only with specialist input:

– Pre-existing renal disease, single kidney, or elevated risk of renal dysfunction (uncontrolled diabetes/hypertension, low baseline eGFR): avoid high-dose (>3–5 g/day) without nephrology input.[27][7]

– Pregnancy/breastfeeding: human efficacy/safety unproven; use only within research.[8]

– Bipolar disorder / mania history: caution given isolated hypomania reports.[18]

Regulatory/ethical status: CrM is a food supplement (not an MHRA-licensed medicine); all longevity uses are off-label. Practice should be framed as adjunctive care with documented informed consent, ideally within an audit/registry; mortality and dementia-prevention claims should be reserved for research settings only.

5. Assessment and baseline work-up

– History/examination: dietary pattern (meat intake, vegetarian status), current RT/physical activity, renal/hepatic history, cardiometabolic risk, medications (nephrotoxic agents, metformin, diuretics), pregnancy status, psychiatric history.

– Functional/phenotype baseline (if targeting sarcopenia/frailty): grip strength, chair-stand or timed-up-and-go, gait speed; consider DXA lean mass if available.[10][12]

– Baseline bloods: serum creatinine + eGFR (essential — see monitoring caveat below), U&E, and LFTs if hepatic concern. Routine screening in healthy individuals is arguably unnecessary but is prudent before longer-term dosing.[27]

– Risk stratification: low risk = healthy, normal eGFR, RT-engaged; moderate = older/multimorbid or borderline renal function; high = CKD, single kidney, pregnancy, bipolar disorder — reserve for specialist/research.

– Document: baseline eGFR/creatinine, functional metrics, indication and consent, so the expected benign rise in serum creatinine is not later misread as renal injury.

6. Dosing regimens and practical implementation

Robustly supported (human data):

– Maintenance-only (preferred for longevity): 3–5 g/day of creatine monohydrate, single daily dose, continuously. 3 g/day for ~28 days achieves the same muscle saturation as rapid loading, just more slowly. For musculoskeletal benefit in older adults/postmenopausal women, use ≥5 g/day combined with RT — lower doses (≤3 g/day) without RT are ineffective for lean mass/strength.[3][1][13]

– Optional rapid loading: ~20 g/day in 4 divided doses for 5–7 days, then 2–5 g/day maintenance — faster saturation but no long-term advantage and more GI/fluid-weight effects.[3][1]

– Formulation: plain creatine monohydrate is the best-evidenced, cheapest form; “novel” forms confer no proven advantage.

– Response: ~10–15% are non-responders (already high muscle stores).[1]

Extrapolated / caution (weaker data):

– Higher doses (0.1–0.14 g/kg/day) used in bone/postmenopausal trials showed no BMD benefit and are not recommended for that purpose.[21][22]

– Doses of 2–10 g/day used in mood trials are experimental adjuncts only.[18]

Non-pharmacological pairing: the intervention with the best evidence is CrM + progressive resistance training (typically ≥2–3 sessions/week over ≥6–12 weeks) — RT is effectively required to realise musculoskeletal benefit.[10][13]

7. Monitoring, safety and follow-up

– Safety profile: CrM is well tolerated. Commonest effects are weight/fluid gain, GI upset (nausea, diarrhoea) and cramping, mostly with loading doses. No consistent evidence of liver or kidney harm in healthy adults over months of use.[28][27]

– Key monitoring caveat — serum creatinine: CrM causes a small, expected rise in serum creatinine (≈0.07–0.13 mg/dL) from metabolic turnover, without meaningful change in urea or eGFR. Interpret creatinine cautiously; if renal concern arises, use cystatin C-based eGFR to avoid misclassification.[29][30]

– Timepoints: review symptoms and adherence at 6–12 weeks; recheck renal function at ~3 months then 6–12 monthly in moderate-risk patients. Reassess functional/strength metrics at 3–6 months to judge benefit.

– Actions on abnormal findings: unexplained eGFR decline (beyond the expected creatinine shift) → withhold and investigate/refer. New hypomania/mania in a mood-indication patient → stop and refer.

– Interactions: theoretical additive renal risk with nephrotoxic drugs (NSAIDs, aminoglycosides); caution alongside other agents affecting renal handling. No major established drug interactions in healthy adults.

– Special populations: avoid high-dose in CKD/renal risk; pregnancy/breastfeeding — research only; in frailty/advanced age, pair with RT and monitor renal function.[27][7][8]

8. Contraindications and cautions

– Absolute (relative to current evidence): significant renal impairment/active kidney disease where risk is unquantified — avoid without nephrology input.

– Relative / specialist advice: diabetes or hypertension with reduced GFR; single kidney; bipolar disorder; pregnancy/breastfeeding.

– Harm likely to outweigh benefit: use for BMD improvement (null evidence) or as cardiovascular/heart-failure therapy (no proven benefit).[21][22][13][25]

9. Practical management scenarios

Scenario A — Middle-aged adult with cardiometabolic risk factors:

Offer / conditional recommendation. Assess renal function and RT engagement. Shared decision-making: frame as adjunct to lifestyle/exercise with a modest glycaemic signal only alongside exercise.[5] Initiate 3–5 g/day with a concurrent RT programme. Monitor weight, glycaemic markers and renal function at 3 months. Escalate/stop if renal function deteriorates unexpectedly.

Scenario B — Older, frail patient with multimorbidity:

Consider / conditional. Only if renal function adequate and a supervised RT programme is feasible — benefit is contingent on training.[10][12] Check baseline eGFR, grip strength, gait speed. Start 5 g/day (skip loading to minimise GI/fluid effects). Reassess function at 3 months; continue only if functional gains or good tolerance. Refer to physiotherapy for RT; stop if no RT is possible.

Scenario C — Patient already under specialist care (e.g. depression on an SSRI):

Restrict to research / specialist-directed adjunct. Evidence for mood is very low certainty with a bias signal.[17][18] Only add CrM in coordination with the treating psychiatrist, document consent, watch for hypomania, and prefer enrolment in a trial where available.

10. Research gaps and future directions

– Long-term (>1–2 yr) renal safety RCTs, particularly in older adults and those with borderline renal function.[29][30]

– Adequately powered RCTs of creatine alone (without RT) for cognition and for hard cognitive/dementia outcomes, not just memory surrogates.[14][15]

– Definitive mood RCTs disentangling true effect from publication bias, and defining populations most likely to respond.[17][18]

– Frailty, falls and fracture endpoints in sarcopenic/osteosarcopenic populations, which have not been directly studied.[26]

– Mortality and cardiometabolic hard outcomes — currently only observational/very-low-certainty; should remain research- or registry-based.[24][25]

Overall, the defensible longevity use today is CrM 3–5 g/day (≥5 g/day for musculoskeletal aims) combined with resistance training in appropriately screened, renally healthy adults, presented honestly as low-risk but of modest, mostly surrogate-level, benefit.

References

1. Food for thought: Physiological considerations for nutritional ergogenic efficacy. Wickham KA, Spriet LL. Scandinavian Journal of Medicine & Science in Sports. 2024;34(1):e14307. doi:10.1111/sms.14307.
2. “Heads Up” for Creatine Supplementation and Its Potential Applications for Brain Health and Function. Candow DG, Forbes SC, Ostojic SM, et al. Sports Medicine (Auckland, N.Z.). 2023;53(Suppl 1):49-65. doi:10.1007/s40279-023-01870-9.
3. Muscle Creatine Loading in Men. Hultman E, Söderlund K, Timmons JA, Cederblad G, Greenhaff PL. Journal of Applied Physiology (Bethesda, Md. : 1985). 1996;81(1):232-7. doi:10.1152/jappl.1996.81.1.232.
4. The Combination of Physical Exercise with Muscle‐Directed Antioxidants to Counteract Sarcopenia: A Biomedical Rationale for Pleiotropic Treatment with Creatine and Coenzyme Q10. Guescini M, Tiano L, Genova ML, et al. Oxidative Medicine and Cellular Longevity. 2017;2017:7083049. doi:10.1155/2017/7083049.
5. Creatine Supplementation and Glycemic Control: A Systematic Review. Pinto CL, Botelho PB, Pimentel GD, Campos-Ferraz PL, Mota JF. Amino Acids. 2016;48(9):2103-29. doi:10.1007/s00726-016-2277-1.
6. Effects of High-Load, Velocity-Intentional Variable Resistance Training Combined With Creatine Supplementation on Neuroplasticity, Oxidative Stress, Inflammation, Physical Function, Cognitive Performance and Quality of Life in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Fernandez-Garrido J, Martin EG, Saez-Berlanga A, et al. Experimental Gerontology. 2026;218:113122. doi:10.1016/j.exger.2026.113122.
7. Creatine Supplementation in Patients With Kidney Disease – Harm or Benefit?. Pereira JP, Leal VO, Trigueira P, et al. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association – European Renal Association. 2026;:gfag169. doi:10.1093/ndt/gfag169.
8. Creatine for Women in Pregnancy for Neuroprotection of the Fetus. Dickinson H, Bain E, Wilkinson D, et al. The Cochrane Database of Systematic Reviews. 2014;(12):CD010846. doi:10.1002/14651858.CD010846.pub2.
9. The Gut Microbiota Alleviates Depression by Remodeling Gut-Brain Energy Metabolism. Lu CL, Ren J, Lei Y, et al. Cell Metabolism. 2026;38(6):1201-1217.e8. doi:10.1016/j.cmet.2026.03.002.
10. Creatine Supplementation During Resistance Training in Older Adults-a Meta-Analysis. Devries MC, Phillips SM. Medicine and Science in Sports and Exercise. 2014;46(6):1194-203. doi:10.1249/MSS.0000000000000220.
11. Creatine Supplementation for Older Adults: Focus on Sarcopenia, Osteoporosis, Frailty and Cachexia. Candow DG, Chilibeck PD, Forbes SC, et al. Bone. 2022;162:116467. doi:10.1016/j.bone.2022.116467.
12. Creatine Monohydrate Supplementation for Older Adults and Clinical Populations. Candow DG, Ostojic SM, Chilibeck PD, et al. Journal of the International Society of Sports Nutrition. 2025;22(sup1):2534130. doi:10.1080/15502783.2025.2534130.
13. Creatine Monohydrate for Lean Mass, Strength, and Bone Density in Postmenopausal Women: A Systematic Review and Meta-Analysis. Naddafha S, Antonio J, Kreider RB, Stout JR. Journal of the International Society of Sports Nutrition. 2026;23(1):2668435. doi:10.1080/15502783.2026.2668435.
14. Effects of Creatine Supplementation on Memory in Healthy Individuals: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Prokopidis K, Giannos P, Triantafyllidis KK, et al. Nutrition Reviews. 2023;81(4):416-427. doi:10.1093/nutrit/nuac064.
15. Creatine and Cognition in Aging: A Systematic Review of Evidence in Older Adults. Marshall S, Kitzan A, Wright J, Bocicariu L, Nagamatsu LS. Nutrition Reviews. 2025;:nuaf135. doi:10.1093/nutrit/nuaf135.
16. The Effects of Creatine Supplementation on Cognitive Performance-a Randomised Controlled Study. Sandkühler JF, Kersting X, Faust A, et al. BMC Medicine. 2023;21(1):440. doi:10.1186/s12916-023-03146-5.
17. Creatine Supplementation for Treating Symptoms of Depression: A Systematic Review and Meta-Analysis. Eckert I, Lima J, Dariva AA. The British Journal of Nutrition. 2025;:1-37. doi:10.1017/S0007114525105588.
18. The Effect of Creatine Monohydrate on Mental Disorders: A Systematic Review of Randomized Controlled Trials: Effet Du Monohydrate De Créatine Sur Les Troubles Mentaux : Examen Systématique Des Essais Contrôlés À Répartition Aléatoire. Jeryous Fares B, Zhou C, Fabiano N, et al. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2026;:7067437251408171. doi:10.1177/07067437251408171.
19. Efficacy and Safety Profile of Oral Creatine Monohydrate in Add-on to Cognitive-Behavioural Therapy in Depression: An 8-Week Pilot, Double-Blind, Randomised, Placebo-Controlled Feasibility and Exploratory Trial in an Under-Resourced Area. Sherpa NN, De Giorgi R, Ostinelli EG, et al. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology. 2025;90:28-35. doi:10.1016/j.euroneuro.2024.10.004.
20. Creatine Supplementation in Type 2 Diabetic Patients: A Systematic Review of Randomized Clinical Trials. Mancini de Sousa M, Nakata MTK, Baldini CES, et al. Current Diabetes Reviews. 2022;18(3):e120721194709. doi:10.2174/1573399817666210712151737.
21. A 2-Yr Randomized Controlled Trial on Creatine Supplementation During Exercise for Postmenopausal Bone Health. Chilibeck PD, Candow DG, Gordon JJ, et al. Medicine and Science in Sports and Exercise. 2023;55(10):1750-1760. doi:10.1249/MSS.0000000000003202.
22. Creatine Supplementation (3 G/D) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial. Sales LP, Pinto AJ, Rodrigues SF, et al. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2020;75(5):931-938. doi:10.1093/gerona/glz162.
23. Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women. Chilibeck PD, Candow DG, Landeryou T, Kaviani M, Paus-Jenssen L. Medicine and Science in Sports and Exercise. 2015;47(8):1587-95. doi:10.1249/MSS.0000000000000571.
24. Dietary Creatine Intake and All-Cause Mortality Among U.S. Adults: A Linked Mortality Analysis From the NHANES Study. Ostojic SM. Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme. 2025;. doi:10.1139/apnm-2025-0001.
25. Creatine and Creatine Analogues in Hypertension and Cardiovascular Disease. Horjus DL, Oudman I, van Montfrans GA, Brewster LM. The Cochrane Database of Systematic Reviews. 2011;(11):CD005184. doi:10.1002/14651858.CD005184.pub2.
26. The Potential of Creatine Monohydrate Supplementation in the Management of Osteosarcopenia. Candow DG, Kirk B, Chilibeck PD, Duque G. Current Opinion in Clinical Nutrition and Metabolic Care. 2025;28(3):235-239. doi:10.1097/MCO.0000000000001118.
27. Studies on the Safety of Creatine Supplementation. Kim HJ, Kim CK, Carpentier A, Poortmans JR. Amino Acids. 2011;40(5):1409-18. doi:10.1007/s00726-011-0878-2.
28. American College of Sports Medicine Position Stand. Nutrition and Athletic Performance. Rodriguez NR, Di Marco NM, Langley S. Medicine and Science in Sports and Exercise. 2009;41(3):709-31. doi:10.1249/MSS.0b013e31890eb86.
29. The Effect of Creatine Supplementation on Kidney Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Tsiaras A, Loufopoulos G, Theodoridis X, et al. Journal of Renal Nutrition : The Official Journal of the Council on Renal Nutrition of the National Kidney Foundation. 2026;:S1051-2276(26)00082-8. doi:10.1053/j.jrn.2026.04.010.
30. Effect of Creatine Supplementation on Kidney Function: A Systematic Review and Meta-Analysis. Naeini EK, Eskandari M, Mortazavi M, Gholaminejad A, Karevan N. BMC Nephrology. 2025;26(1):622. doi:10.1186/s12882-025-04558-6.